• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Axogen Inc. (Amendment)

    2/14/24 3:22:18 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AXGN alert in real time by email
    SC 13G/A 1 arrowmark-axgn123123a7.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)*



    Axogen, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

    05463X106

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No. 05463X106
     SCHEDULE 13G/A
    Page 2 of 6 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    ArrowMark Colorado Holdings, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    5,152,300
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    5,152,300
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    5,152,300
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    11.97%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     
     

     

    CUSIP No.  05463X106
     SCHEDULE 13G/A
    Page 3 of  6 Pages

     

    Item 1.(a) Name of Issuer

    Axogen, Inc.

    (b) Address of Issuer’s Principal Executive Offices

    13631 Progress Blvd., Suite 400

    Alachua, FL 32615

    Item 2.(a) Name of Person Filing

    ArrowMark Colorado Holdings, LLC

    (b) Address of Principal Business Office, or, if none, Residence

    100 Fillmore Street, Suite 325

    Denver, Colorado 80206

    (c) Citizenship

    Please refer to Item 4 on each cover sheet for each filing person

     (d) Title of Class of Securities

    Common Stock, par value $0.01 per share

     (e) CUSIP No.:

    05463X106

     
     

     

    CUSIP No.  05463X106
     SCHEDULE 13G/A
    Page 4 of 6 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 05463X106
     SCHEDULE 13G/A
    Page 5 of 6 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: 5,152,300

    (b) Percent of class: 11.97%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 5,152,300

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 5,152,300

    (iv) Shared power to dispose or to direct the disposition of: 0

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable

     Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

      

     
     
    CUSIP No. 05463X106
     SCHEDULE 13G/A
    Page 6 of 6 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

      ArrowMark Colorado Holdings, LLC
           
      By:  Richard Grove
        Name:  Richard Grove
        Title:  Chief Compliance Officer

     

     

     

     

     

     

     

    Get the next $AXGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXGN

    DatePrice TargetRatingAnalyst
    3/17/2025$30.00Buy
    Lake Street
    7/1/2024$13.00Outperform
    Raymond James
    11/11/2022$15.00Buy
    Jefferies
    5/9/2022$10.00 → $15.00Hold → Buy
    Canaccord Genuity
    3/11/2022$21.00Overweight
    Cantor Fitzgerald
    11/4/2021$25.00 → $20.00Market Outperform
    JMP Securities
    More analyst ratings

    $AXGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Marketing Officer Kemp Jens

      4 - Axogen, Inc. (0000805928) (Issuer)

      3/26/25 4:53:56 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Innovation Officer Devinney Erick Wayne

      4 - Axogen, Inc. (0000805928) (Issuer)

      3/26/25 4:52:55 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Dale Michael D

      4 - Axogen, Inc. (0000805928) (Issuer)

      3/26/25 4:48:12 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on AxoGen with a new price target

      Lake Street initiated coverage of AxoGen with a rating of Buy and set a new price target of $30.00

      3/17/25 8:23:19 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Raymond James initiated coverage on AxoGen with a new price target

      Raymond James initiated coverage of AxoGen with a rating of Outperform and set a new price target of $13.00

      7/1/24 7:31:31 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Jefferies resumed coverage on AxoGen with a new price target

      Jefferies resumed coverage of AxoGen with a rating of Buy and set a new price target of $15.00

      11/11/22 9:07:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXGN
    Financials

    Live finance-specific insights

    See more
    • Axogen, Inc. Reports 2025 First Quarter Financial Results

      ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025. First Quarter Financial Results First quarter revenue was $48.6 million, a 17.4% increase compared to the first quarter of 2024.For the first quarter of 2025, gross margin was 71.9%, down from 78.8% for the first quarter of 2024.Net loss for the quarter was $3.8 million, or $0.08 per share, compared to $6.6 million, or $0.15 per share for the first quarter of 2024.Adjusted net loss for the quart

      5/8/25 7:05:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

      ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter financial results on Thursday, May 8, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visit

      4/24/25 8:04:18 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results

      ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Financial Results and Business Highlights Fourth quarter revenue was $49.4 million, a 15.1% increase compared to the fourth quarter of 2023.Gross margin was 76.1% for the fourth quarter compared to 74.6% for the fourth quarter of 2023.Net income for the quarter was $0.4 million, or $0.01 per share, compared to net loss of $3.9 million, or $0.09 per shar

      2/25/25 7:00:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Axogen Inc.

      SC 13G/A - Axogen, Inc. (0000805928) (Subject)

      11/14/24 3:31:14 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Axogen Inc.

      SC 13G - Axogen, Inc. (0000805928) (Subject)

      11/7/24 4:34:48 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Axogen Inc.

      SC 13G/A - Axogen, Inc. (0000805928) (Subject)

      9/10/24 4:00:03 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axogen, Inc. Reports 2025 First Quarter Financial Results

      ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025. First Quarter Financial Results First quarter revenue was $48.6 million, a 17.4% increase compared to the first quarter of 2024.For the first quarter of 2025, gross margin was 71.9%, down from 78.8% for the first quarter of 2024.Net loss for the quarter was $3.8 million, or $0.08 per share, compared to $6.6 million, or $0.15 per share for the first quarter of 2024.Adjusted net loss for the quart

      5/8/25 7:05:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen Announces Chief Financial Officer Transition

      ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Lindsey Hartley, CPA, as Chief Financial Officer, effective May 12, 2025. Ms. Hartley, who currently serves as Vice President, Corporate Controller at Axogen, will succeed Nir Naor, who is departing to pursue other opportunities. Mr. Naor will remain with the Company in an advisory capacity until July 1, 2025, to ensure a smooth transition. "I want to express my sincere gratitude to Nir for his service to Axogen," said Michael Dale, President, Chief Executive O

      5/8/25 7:00:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

      ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter financial results on Thursday, May 8, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visit

      4/24/25 8:04:18 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXGN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Axogen Inc.

      10-Q - Axogen, Inc. (0000805928) (Filer)

      5/8/25 4:38:29 PM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

      8-K - Axogen, Inc. (0000805928) (Filer)

      5/8/25 7:10:55 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by Axogen Inc.

      DEF 14A - Axogen, Inc. (0000805928) (Filer)

      4/30/25 7:07:43 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AXGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Axogen Announces Chief Financial Officer Transition

      ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Lindsey Hartley, CPA, as Chief Financial Officer, effective May 12, 2025. Ms. Hartley, who currently serves as Vice President, Corporate Controller at Axogen, will succeed Nir Naor, who is departing to pursue other opportunities. Mr. Naor will remain with the Company in an advisory capacity until July 1, 2025, to ensure a smooth transition. "I want to express my sincere gratitude to Nir for his service to Axogen," said Michael Dale, President, Chief Executive O

      5/8/25 7:00:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of the coverage and reimbursement-related strategies required to support Axogen's mission to establish restoration of peripheral nerve function as an expected standard of care. Mr. Ditto brings over 15 years of leadership experience in the medical device industry, with a pr

      3/24/25 8:00:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs. Mr. Bishop will report to Michael Dale, President, and Chief Executive Officer, and will lead the development and execution of domestic and international regulatory strategies to advance company objectives related to new product development, market approval, market development and other regulatory initiatives. Mr. Bishop will oversee all facets of Axogen's regulatory affairs, maintenance of Axogen product

      2/3/25 8:00:00 AM ET
      $AXGN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care